Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,368.85
(
-1.67%
)
US TECH 100
22,405.20
(
-2.38%
)
Dow Jones
45,166.64
(
-1.73%
)
Brent Oil
106.89
(
0.00%
)
Bitcoin
66,859.98
(
0.78%
)
News Focus
News Focus
Post# of 257302
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122817
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 217207

Friday, 02/16/2018 8:40:38 AM

Friday, February 16, 2018 8:40:38 AM

Post# of 257302
Mavyret scripts continue ramp-up:

• ABBV/ENTA’s HCV-new-patient share=39.2% in week ending 2/9/18, up from 35.2% in the prior week (according to IMS).

• ABBV/ENTA’s HCV-total-patient-share=34.2% in week ending 2/9/18, up from 29.6% in the prior week (according to IMS).

• Both NRx=39.2% and TRx=35.2% are the highest-ever weekly figures reported by IMS for ABBV/ENTA’s HCV share.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today